{"DataElement":{"publicId":"6042259","version":"1","preferredName":"SGPT (ALT) Or SGOT (AST) Significant Increase Since Baseline Yes No Indicator","preferredDefinition":"A yes or no response to indicate whether the patient had a significant increase in SGPT (ALT) Or SGOT (AST) since baseline.","longName":"ALT_AST_INCRS_SINC_BASLNE_IND","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"6042258","version":"1","preferredName":"SGPT (ALT) Or SGOT (AST) Significant Increase Since Baseline","preferredDefinition":"Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI)_An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._Activity measured as a test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferases (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. (NCI)_A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent._A process of becoming larger, more numerous, more important, or more likely._Subsequent to; after._A starting point to which things may be compared.","longName":"6042255v1.0:6042256v1.0","context":"DCP","contextVersion":"1","ObjectClass":{"publicId":"6042255","version":"1","preferredName":"SGPT (ALT) Or SGOT (AST)","preferredDefinition":"Activity measured as a test of liver function, human Glutamic-Pyruvate Transaminases (Alanine Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Glutamic Pyruvic Transaminases mediate conversion of major intermediate metabolites, catalyzing reversible transamination between alanine and alpha-ketoglutarate to form pyruvate and glutamate. (NCI):An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.:Activity measured as a test of liver function, 46/47-kDa homodimeric human Aspartate Aminotransferases (Class-I Pyridoxal-Phosphate-Dependent Aminotransferase Family) are pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. (NCI)","longName":"C25293:C37998:C25202","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alanine Aminotransferase","conceptCode":"C25293","definition":"A family of pyridoxal phosphate-dependent enzymes involved in cellular nitrogen metabolism, amino acid metabolism, and liver gluconeogenesis. Alanine aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-alanine to alpha-ketoglutarate forming pyruvate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Aspartate Aminotransferase","conceptCode":"C25202","definition":"A family of pyridoxal phosphate-dependent enzymes involved in amino acid metabolism and in the urea and tricarboxylic acid cycles. Aspartate aminotransferase specifically and reversibly catalyzes the transfer of an amino group from L-aspartate to alpha-ketoglutarate forming oxaloacetate and L-glutamate.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"603AA1F4-F440-0DEF-E053-F662850A3AEE","latestVersionIndicator":"Yes","beginDate":"2017-12-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-13","modifiedBy":"ONEDATA","dateModified":"2017-12-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6042256","version":"1","preferredName":"Significant Increase Since Baseline","preferredDefinition":"A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent.:A process of becoming larger, more numerous, more important, or more likely.:Subsequent to; after.:A starting point to which things may be compared.","longName":"C41130:C25533:C45325:C25213","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Significant","conceptCode":"C41130","definition":"A term applied to differences, correlations, cause-and-effect relationships, etc., to indicate that they are noticeable, probably too closely correlated to be attributed to chance and therefore indicating a systematic relation: substantial, fairly large; also having consequence or import, important in effect or meaning. In statistics significant ordinarily indicates a probability of not less than 95 percent, while highly significant indicates a probability of not less than 99 percent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Increase","conceptCode":"C25533","definition":"A process of becoming larger, more numerous, more important, or more likely.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Since","conceptCode":"C45325","definition":"Subsequent to; after.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Baseline","conceptCode":"C25213","definition":"A starting point to which things may be compared.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"603AA1F4-F453-0DEF-E053-F662850A3AEE","latestVersionIndicator":"Yes","beginDate":"2017-12-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-13","modifiedBy":"ONEDATA","dateModified":"2017-12-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"603AA1F4-F464-0DEF-E053-F662850A3AEE","latestVersionIndicator":"Yes","beginDate":"2017-12-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-13","modifiedBy":"LUY","dateModified":"2018-01-08","changeDescription":"12/13/2017 wz created for DCP SVAR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3506068","version":"1","preferredName":"Yes No Indicator","preferredDefinition":"The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"YES_NO_IND","context":"NCI Standards","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3197154","version":"1","preferredName":"No","longName":"3197154","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-55AD-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":"2022.12.28 Alt VM added per ticket request CADSR0001837. aj","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75C2-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C37A1BEB-75CC-B6C9-E040-BB89AD434179","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"ONEDATA","dateModified":"2012-06-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"3502157","version":"1","preferredName":"Yes No Indicator Value Domains","preferredDefinition":"Conceptual domain that includes value meanings to be used for Indicator Value Meanings such as Yes, No, Unknown, No Applicable","longName":"YES_NO_IND_VD","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C377DE0C-8C3E-DCA8-E040-BB89AD431B6D","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CURTIST","dateCreated":"2012-06-27","modifiedBy":"CURTIST","dateModified":"2012-06-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2421125","version":"1","preferredName":"Ind-2","preferredDefinition":"A caDSR representation term that is used to indicate a question with permissible values of yes/no","longName":"C38147","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes or No Response","conceptCode":"C38147","definition":"A response or indicator that can have a value of either yes or no.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RETIRED ARCHIVED","registrationStatus":"Retired","id":"0303DF01-F4B4-15EC-E044-0003BA3F9857","latestVersionIndicator":"No","beginDate":"2005-10-18","endDate":"2016-04-27","createdBy":"SHIDED","dateCreated":"2005-10-18","modifiedBy":"TAYLORT","dateModified":"2020-10-03","changeDescription":"10.3.20 TL changed WFS from RETIRED PHASED OUT to RETIRED ARCHIVED. Changed Workflow Status DBW 04-27-2016","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C37A1BEB-75AE-B6C9-E040-BB89AD434179","latestVersionIndicator":"Yes","beginDate":"2012-06-27","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2012-06-27","modifiedBy":"TSESU","dateModified":"2023-08-16","changeDescription":"8/29/17 tt added CSI per Round 5 finalization task. 3/12/17 jk added Standard reg status; ownership transfered from CTEP to NCI Standards with concurrence of CTEP/Brian Campbell. jk","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5889179","version":"1","longName":"NWU2016-08-02","context":"DCP"}]}],"AlternateNames":[{"name":"DCP","type":"USED_BY","context":"DCP"}],"ReferenceDocuments":[{"name":"Has the patient had a signifi","type":"Preferred Question Text","description":"Has the patient had a significant increase in ALT or AST since baseline?","url":null,"context":"DCP"},{"name":"DCP CRF Text","type":"Alternate Question Text","description":"Has the patient had any increases in ALT or AST >5x upper limit of normal or ALT or AST increase to >3x baseline levels?","url":null,"context":"DCP"},{"name":"DCP CRF Text 1","type":"Alternate Question Text","description":"In the past 2 weeks, has the patient had any increases in ALT or AST >5x upper limit of normal or ALT or AST increase to >3x baseline levels?","url":null,"context":"DCP"}],"origin":"DCP:Division of Cancer Prevention","workflowStatus":"RELEASED","registrationStatus":"Application","id":"603A8E12-29EA-1D3A-E053-F662850AC049","latestVersionIndicator":"Yes","beginDate":"2017-12-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-12-13","modifiedBy":"TITARENKOI","dateModified":"2020-04-29","changeDescription":"12/13/2017 wz created for DCP SVAR.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}